RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Medicenna Therapeutics Stock

Medicenna Therapeutics P/E 2025

Medicenna Therapeutics P/E

-5.46

Ticker

MDNA.TO

ISIN

CA58490H1073

As of Aug 4, 2025, Medicenna Therapeutics's P/E ratio was -5.46, a 21.06% change from the -4.51 P/E ratio recorded in the previous year.

The Medicenna Therapeutics P/E history

Medicenna Therapeutics Aktienanalyse

What does Medicenna Therapeutics do?

Medicenna Therapeutics Corp is a biopharmaceutical company based in Canada that specializes in the development of treatments for serious diseases such as cancer or neurodegenerative disorders. The company was founded in 2011 and went public in 2019. Medicenna's business model is based on the use of state-of-the-art technologies and innovative approaches to disease treatment. This includes the use of immunotherapies that specifically strengthen the patient's own immune system to help fight diseases. Medicenna is divided into several divisions, each with different focuses. The first division is the development of treatments for brain tumors such as glioblastomas, which can occur in adults and children. The company has developed a unique technology called "Superkines" that enables it to manipulate the patient's immune system to attack and destroy brain tumors. This technology has already been tested in clinical trials with promising results. Another division of Medicenna specializes in the treatment of severe cancers such as lung cancer or triple-negative breast cancer. The company uses both immunotherapies and targeted therapies to inhibit the growth of cancer cells and strengthen the patient's own immune system. In addition to drug development, Medicenna also offers consulting services to support other companies in the development of therapies. This includes identifying potential target molecules and optimizing drug candidates. Overall, Medicenna has several promising products in its pipeline, currently in different phases of clinical development. The most advanced product is MDNA55, a superkine for the treatment of glioblastoma, which is already in clinical phase III trials. Other promising products include MDNA19, a targeted immunotherapy for the treatment of lung cancer, and MDNA57, a therapy for triple-negative breast cancer. All in all, Medicenna has established itself as one of the most promising biotech companies in the market. With its innovative therapy approaches and promising products, the company is well positioned to make a sustainable impact on the field of biomedicine and help patients fight serious diseases. Medicenna Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/E Details

Deciphering Medicenna Therapeutics's P/E Ratio

The Price to Earnings (P/E) Ratio of Medicenna Therapeutics is a vital metric that investors and analysts use to determine the company’s market value relative to its earnings. It is calculated by dividing the current stock price by the earnings per share (EPS). A higher P/E ratio could suggest that investors are expecting higher future growth, while a lower ratio may indicate a potentially undervalued company or lower growth expectations.

Year-to-Year Comparison

Assessing Medicenna Therapeutics's P/E ratio on a yearly basis provides insights into the valuation trends and investor sentiment. An increasing P/E ratio over the years signifies growing investor confidence and expectations for future earnings growth, while a decreasing ratio may reflect concerns over the company's profitability or growth prospects.

Impact on Investments

The P/E ratio of Medicenna Therapeutics is a key consideration for investors aiming to balance risk and reward. A comprehensive analysis of this ratio, in conjunction with other financial indicators, aids investors in making informed decisions regarding buying, holding, or selling the company’s stocks.

Interpreting P/E Ratio Fluctuations

Fluctuations in Medicenna Therapeutics’s P/E ratio can be attributed to various factors including changes in earnings, stock price movements, and shifts in investor expectations. Understanding the underlying reasons for these fluctuations is essential for predicting future stock performance and assessing the company's intrinsic value.

Frequently Asked Questions about Medicenna Therapeutics stock

What is the price-to-earnings ratio of Medicenna Therapeutics?

The price-earnings ratio of Medicenna Therapeutics is currently -5.46.

How has the price-earnings ratio of Medicenna Therapeutics changed compared to last year?

The price-to-earnings ratio of Medicenna Therapeutics has increased by 21.06% increased compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Medicenna Therapeutics high compared to other companies?

Yes, the price-to-earnings ratio of Medicenna Therapeutics is high compared to other companies.

How does an increase in the price-earnings ratio of Medicenna Therapeutics affect the company?

An increase in the price-earnings ratio of Medicenna Therapeutics would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Medicenna Therapeutics affect the company?

A decrease in the price-earnings ratio of Medicenna Therapeutics would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Medicenna Therapeutics?

Some factors that influence the price-earnings ratio of Medicenna Therapeutics are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Medicenna Therapeutics pay?

Over the past 12 months, Medicenna Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Medicenna Therapeutics is expected to pay a dividend of 0 CAD.

What is the dividend yield of Medicenna Therapeutics?

The current dividend yield of Medicenna Therapeutics is .

When does Medicenna Therapeutics pay dividends?

Medicenna Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Medicenna Therapeutics?

Medicenna Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Medicenna Therapeutics?

For the upcoming 12 months, dividends amounting to 0 CAD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Medicenna Therapeutics located?

Medicenna Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Medicenna Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Medicenna Therapeutics from 8/4/2025 amounting to 0 CAD, you needed to have the stock in your portfolio before the ex-date on 8/4/2025.

When did Medicenna Therapeutics pay the last dividend?

The last dividend was paid out on 8/4/2025.

What was the dividend of Medicenna Therapeutics in the year 2024?

In the year 2024, Medicenna Therapeutics distributed 0 CAD as dividends.

In which currency does Medicenna Therapeutics pay out the dividend?

The dividends of Medicenna Therapeutics are distributed in CAD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Medicenna Therapeutics

Our stock analysis for Medicenna Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Medicenna Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.